Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
Type 2 diabetes mellitus (T2DM) management is complex, with few patients successfully achieving recommended glycemic targets with monotherapy, most progressing to combination therapy, and many eventually requiring insulin. Sodium glucose cotransporter 2 (SGLT2) inhibitors are an emerging class of an...
Saved in:
Main Author: | Andrew Ahmann (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2015-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Safety of Empagliflozin as Add-On Therapy in Patients of Type-2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2022) -
Influence of Adding Empagliflozin to Conventional Anti-diabetic Therapy on Quality of Life Scale for Type 2 Diabetic Patients
by: Hadeel Delman Najim, et al.
Published: (2024) -
Basal insulin analogues in the diabetes mellitus type 2 control - economic aspects
by: D. Yu. Belousov, et al.
Published: (2018) -
Evaluating Impact of Empagliflozin on Lipid Profile of Patients of Type 2 Diabetes Mellitus
by: Nauman Wazir, et al.
Published: (2022) -
Economic perspectives for effective control of diabetes mellitus type 2 with fixed combination of basal insulin analog and GLP-1 agonist
by: S. K. Zyryanov, et al.
Published: (2019)